Clinical Cancer Research, Vol 3, Issue 9 1565-1569, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma

J Herrada, RB Iyer, EN Atkinson, N Sneige, AU Buzdar and GN Hortobagyi
Departments of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

The purpose of this study was to correlate physical examination and sonographic and mammographic measurements of breast tumors and regional lymph nodes with pathological findings and to evaluate the effect of neoadjuvant chemotherapy on clinical Tumor-Node-Metastasis stage by noninvasive methods. This was a retrospective analysis of 100 patients with locally advanced breast cancer registered and treated in prospective trials of neoadjuvant chemotherapy. All patients received four cycles of a doxorubicin-containing regimen and had noninvasive evaluation of the primary tumor and regional lymph nodes before and after neoadjuvant chemotherapy by physical examination, sonography, and mammography and underwent breast surgery and axillary dissection within 5 weeks after completion of neoadjuvant chemotherapy. The correlations between clinical and pathological measurements were determined by Spearman rank correlation analysis. A proportional odds model was used to examine predictive values. Eighty-three patients had both a clinically detectable primary tumor and lymph node metastases. Sixty-four patients had a decrease in Tumor-Node-Metastasis stage after chemotherapy. For 54% of patients, there was concordance in clinical response between the primary tumor and lymph node compartment; for the rest, results were discordant. Physical examination correlated best with pathological findings in the measurement of the primary tumor (P = 0.0003), whereas sonography was the most accurate predictor of size for axillary lymph nodes (P = 0.0005). The combination of physical examination and mammography worked best for assessment of the primary tumor (P = 0.003), whereas combining physical examination with sonography gave optimal evaluation of regional lymph nodes (P = 0.0001). In conclusion, physical examination is the best noninvasive predictor of the real size of locally advanced primary breast cancer, whereas sonography correlates better with the real dimensions of axillary lymph nodes. The combination of physical examination with either mammography or sonography significantly improves the accuracy of noninvasive assessment of tumor dimensions.

This article has been cited by other articles:

				H.-M. Baek, J.-H. Chen, O. Nalcioglu, and M.-Y. Su Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy Ann. Onc., May 1, 2008; 19(5): 1022 - 1024. [Full Text] [PDF]

				M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann. Onc., December 1, 2007; 18(12): 1927 - 1934. [Abstract] [Full Text] [PDF]

				C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]

				F. Peintinger, H. M. Kuerer, K. Anderson, J. C. Boughey, F. Meric-Bernstam, S. E. Singletary, K. K. Hunt, G. J. Whitman, T. Stephens, A. U. Buzdar, et al. Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy Ann. Surg. Oncol., November 1, 2006; 13(11): 1443 - 1449. [Abstract] [Full Text] [PDF]

				S. J. Cleator, A. Makris, S. E. Ashley, R. Lal, and T. J. Powles Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival Ann. Onc., February 1, 2005; 16(2): 267 - 272. [Abstract] [Full Text] [PDF]

				S. Meisamy, P. J. Bolan, E. H. Baker, R. L. Bliss, E. Gulbahce, L. I. Everson, M. T. Nelson, T. H. Emory, T. M. Tuttle, D. Yee, et al. Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo 1H MR Spectroscopy--A Pilot Study at 4 T Radiology, November 1, 2004; 233(2): 424 - 431. [Abstract] [Full Text] [PDF]

				E. Thomas, F. A. Holmes, T. L. Smith, A. U. Buzdar, D. K. Frye, G. Fraschini, S. E. Singletary, R. L. Theriault, M. D. McNeese, F. Ames, et al. The Use of Alternate, Non-Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial J. Clin. Oncol., June 15, 2004; 22(12): 2294 - 2302. [Abstract] [Full Text] [PDF]

				I. Bedrosian, D. Bedi, H. M. Kuerer, B. D. Fornage, L. Harker, M. I. Ross, F. C. Ames, S. Krishnamurthy, B. S. Edeiken-Monroe, F. Meric, et al. Impact of Clinicopathological Factors on Sensitivity of Axillary Ultrasonography in the Detection of Axillary Nodal Metastases in Patients With Breast Cancer Ann. Surg. Oncol., November 1, 2003; 10(9): 1025 - 1030. [Abstract] [Full Text] [PDF]

				G. Lawrence, J. Crawford, F. Sherman, J. A. van der Hage, and C. J.H. van de Velde Evaluating Neoadjuvant Chemotherapy in Breast Cancer J. Clin. Oncol., June 15, 2002; 20(12): 2905 - 2907. [Full Text] [PDF]

				R. Rouzier, J.-M. Extra, J. Klijanienko, M.-C. Falcou, B. Asselain, A. Vincent-Salomon, P. Vielh, and E. Bourstyn Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes J. Clin. Oncol., March 1, 2002; 20(5): 1304 - 1310. [Abstract] [Full Text] [PDF]

				J. A. van der Hage, C. J.H. van de Velde, J.-P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902 J. Clin. Oncol., November 15, 2001; 19(22): 4224 - 4237. [Abstract] [Full Text]

				W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al. Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617. [Abstract] [Full Text]

				M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, D. Sattler, M. Werner, J. Dose, F. Janicke, H. Graeff, et al. Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1689 - 1695. [Abstract] [Full Text] [PDF]

				K. D. Miller, W. McCaskill-Stevens, J. Sisk, D. M. Loesch, F. Monaco, R. Seshadri, and G. W. Sledge Jr Combination Versus Sequential Doxorubicin and Docetaxel as Primary Chemotherapy for Breast Cancer: A Randomized Pilot Trial of the Hoosier Oncology Group J. Clin. Oncol., October 1, 1999; 17(10): 3033 - 3037. [Abstract] [Full Text] [PDF]

				H. Kaufmann, R. Marone, M. A. Olayioye, J. E. Bailey, and M. Fussenegger Characterization of an N-terminally Truncated Cyclin A Isoform in Mammalian Cells J. Biol. Chem., August 3, 2001; 276(32): 29987 - 29993. [Abstract] [Full Text] [PDF]